Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications.
OBJECTIVE
In this retrospective analysis, we assessed the short-term risk of treatment-emergent diabetes (TED) among patients with schizophrenia during clinical trials of antipsychotic medications.


METHODS
From a non-diabetic cohort of patients with schizophrenia (n=5013), the relationship between baseline non-fasting glucose measurement, presence at baseline of risk factors for diabetes, weight gain and therapy assignment on the risk of treatment-emergent diabetes were assessed.


RESULTS
At the baseline assessment, about a third of patients identified with TED during treatment had non-fasting glucose levels over 7.8 mmol/l and two-thirds had multiple diabetes risk factors. Both baseline non-fasting glucose level and the presence of multiple pre-existing diabetes risk factors appeared to have a major impact on the risk of developing diabetes.


CONCLUSIONS
Overall, risk factors for diabetes in patients with schizophrenia overlap those in the general population. The results also suggest that many patients identified with TED might have had pre-existing glycaemic abnormalities or a high baseline burden of diabetes risk factors.
Cavazzoni
Patrizia
P
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA. p_cavazzoni@lilly.com
Mukhopadhyay
Nitai
N
Carlson
Christopher
C
Breier
Alan
A
Buse
John
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents